Test Your clonoSEQ Knowledge

How much do you know about clonoSEQ MRD testing in clinical practice?

clonoSEQ MRD Quiz

How clinicians are using clonoSEQ in routine practice

clonoSEQ is FDA-cleared for patients with CLL, myeloma, and B-ALL. clonoSEQ may be used to inform care decisions such as reducing or stopping treatment, re-initiating treatment, or assessing treatment response. Explore case studies on how clonoSEQ is used to assess treatment response or inform clinical care decisions to reduce or stop treatment or re-initiate treatment.

View All

Leading expert views on the role of MRD in patient care

The body of evidence supporting MRD assessment in routine patient care is growing. Leading experts share their views on MRD, the evolving role of MRD testing in lymphoid cancers, and insights on how MRD results influence clinical practice decisions.

View All

Dr. Ola Landgren discusses the prognostic value of MRD and its important role in myeloma due to the deep responses now available.

Dr. Hervé Avet-Loiseau explores prognostic factors in myeloma treatment and the future of MRD.

The patient perspective on MRD

Shared decision-making between patients and care teams improves trust and quality of life. Patients offer their stories and insights on the role of MRD testing in their personal treatment journeys.

View All

As a patient with high-risk myeloma, Tim shares his experiences and insights on what MRD testing means for patients.

When experience builds to evidence: Peer-reviewed real-world evidence analysis

Data from clinical trials has demonstrated the prognostic value of MRD within controlled research settings. Do those findings hold true in routine clinical practice? Institutions have published their experience with clonoSEQ and demonstrated how MRD assessment in a real-world setting has the same predictive power as that seen in clinical trials.

View All

The Adaptive experience: observations and analysis of real-world clonoSEQ results

As the leading provider of clinical NGS MRD testing in the U.S., Adaptive Biotechnologies has an unparalleled ability to draw insight from our internal data. Leveraging this unique dataset, we can illustrate how, when and for which patient types MRD testing is currently being used by clinicians. These data also enable publication of novel findings regarding the depth and duration of the response that clonoSEQ-tested patients are achieving.

View All

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.